ARDIZZONI, Andrea
 Distribuzione geografica
Continente #
NA - Nord America 925
EU - Europa 886
AS - Asia 520
OC - Oceania 2
AF - Africa 1
Totale 2.334
Nazione #
US - Stati Uniti d'America 920
CN - Cina 414
FI - Finlandia 239
IE - Irlanda 196
SE - Svezia 192
IT - Italia 149
TR - Turchia 58
DE - Germania 56
SG - Singapore 31
UA - Ucraina 22
IN - India 14
GB - Regno Unito 11
FR - Francia 7
CA - Canada 5
CZ - Repubblica Ceca 5
NL - Olanda 3
IR - Iran 2
NZ - Nuova Zelanda 2
PL - Polonia 2
AT - Austria 1
BE - Belgio 1
EG - Egitto 1
HK - Hong Kong 1
HU - Ungheria 1
LU - Lussemburgo 1
Totale 2.334
Città #
Chandler 260
Dublin 196
Beijing 98
Parma 69
Nanjing 66
Dearborn 62
Izmir 57
Shanghai 52
Ashburn 50
New York 50
Ann Arbor 39
Jacksonville 36
Princeton 35
San Mateo 26
Bremen 25
Wilmington 24
Kunming 22
Jinan 20
Shenyang 16
Singapore 16
Nanchang 15
Tianjin 15
Hefei 14
Jiaxing 12
Hebei 11
Seattle 11
Helsinki 10
Rio Saliceto 8
Boardman 7
Leawood 7
Los Angeles 7
Guangzhou 6
Haikou 6
Hangzhou 6
Norwalk 6
Pune 5
Toronto 5
Woodbridge 5
Zhengzhou 5
Changsha 4
Chengdu 4
Des Moines 4
Taizhou 4
Fuzhou 3
Genoa 3
Houston 3
Ningbo 3
Redwood City 3
Rockville 3
Wuhan 3
Auburn Hills 2
Fontevivo 2
Galatina 2
Huizen 2
Kraków 2
Lanzhou 2
Magdeburg 2
Mestre 2
Monmouth Junction 2
New Delhi 2
Reggio Nell'emilia 2
Taiyuan 2
Ardabil 1
Auckland 1
Augusta 1
Bangalore 1
Berlin 1
Bologna 1
Borås 1
Brno 1
Brussels 1
Cairo 1
Caserta 1
Castel Goffredo 1
Central 1
Chongqing 1
Düsseldorf 1
Gainesville 1
Kocaeli 1
Luxembourg 1
Modena 1
Montegaldella 1
Munich 1
Nürnberg 1
Olomouc 1
Pesaro 1
Pinehaven 1
Prague 1
Santa Clara 1
Sassari 1
Sassuolo 1
Scottsdale 1
Shaoxing 1
Vienna 1
Washington 1
Xian 1
Yicheng 1
Totale 1.476
Nome #
Isolation and characterization of circulating tumor cells in advanced squamous-cell carcinoma of the lung 123
Characterization of gefitinib uptake in NSCLC cell lines 101
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 100
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 90
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 88
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 85
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 81
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 80
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 78
Neoplasie del polmone in Neoplasie del Distretto Toracico 73
Predictive factors of diagnostic accuracy of CT-guided transthoracic fine-needle aspiration for solid noncalcified, subsolid and mixed pulmonary nodules. 72
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 71
Histological subtype analysis of colon cancer: a population-based study. Different sides and different diseases. 71
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients 71
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 70
Strong Notch activation hinders bevacizumab efficacy in advanced colorectal cancer 70
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 65
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 64
CT-guided biopsy of pulmonary nodules: Is pulmonary hemorrhage a complication or an advantage? 64
Role of cell gefitinib metabolism in the response of NSCLC cell lines to gefitinib. 62
Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer 62
Cancer stem cells related marker CD44 and Notch activation in metastatic colon cancer patients 60
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 57
Grading the neuroendocrine tumors of the lung: an evidence-based proposal. 57
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 57
Notch Activation Modulates Bevacizumab Activity by CD44 Positive Cancer Stem Cells in Advanced Colon Cancer 56
Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) 54
ACCURACY OF CYTOLOGY IN THE IDENTIFICATION OF HISTOLOGIC SUBTYPE IN NON-SMALL CELL LUNG CANCER (NSCLC 51
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 51
Synergic anti-proliferative effect of gefitinib and RAD001 in non small cell lung cancer cell lines 51
Preclinical study assessing effects of gefitinib continuation after development of gefitinib resistance in NSCLC with activating EGFR mutations 50
Synergistic effect of PI3K and FAK inhibition in squamous lung cancer cells with reduced PTEN level 50
The maintenance of gefitinib inhibits migration and epithelial-mesenchimal transition of Non-small cell lung cancer cell lines that have become resistant after prolonged gefitinib treatment 50
INCREASED SOLUBLE AND MEMBRANE-BOUND PD-L1 EXPRESSION IN NSCLC CELL LINES TREATED WITH PEMETREXED 49
Effect of dual PI3K and FAK inhibition in squamous lung carcinoma with reduced PTEN level 46
Totale 2.380
Categoria #
all - tutte 7.688
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.688


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020482 92 120 14 12 18 51 44 14 37 54 15 11
2020/2021128 4 8 4 2 21 2 4 6 26 7 42 2
2021/2022120 1 1 1 12 2 0 5 15 9 9 8 57
2022/2023805 70 113 57 63 73 102 5 54 239 0 21 8
2023/2024279 12 21 6 9 24 92 20 18 11 6 14 46
Totale 2.380